Trial Profile
A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Degarelix; Goserelin; Leuprorelin
- Indications Carcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 Sep 2019 Status changed from completed to discontinued.
- 18 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research